Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?

The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer.

Related Keywords

Connecticut ,United States ,Texas ,Houston ,Orlando ,Florida ,New Haven ,American ,America ,Roys Herbst ,Johnv Heymach , ,University Of Texas Md Anderson Cancer Center ,American Association For Cancer Research ,Yale Cancer Center ,Astrazeneca ,American Association ,Cancer Research ,Annual Meeting ,Cancer Center ,Medscape Medical ,South America ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Neoadjuvant ,Biologic Therapy ,Non Small Cell Lung Cancer ,Nsclc ,Small Cell Lung Cancer ,Chemotherapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Surgery ,Immunotherapy ,Lung ,